C. Difficile

Infection control efforts to combat hospital-onset Clostridioides difficile infection may be better spent on health care workers’ hand hygiene compliance and environmental cleaning than on visitor contact precautions, a new study suggests.

Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.

Rates of serious clinical complications of Clostridioides difficile infection rose as the number of recurrent infections increased, underscoring the importance of advancing new treatments to prevent recurrence of the disease, a recent study in SAGE Open Medicine found.

According to one new study, proton-pump inhibitors (PPI) exposure demonstrated a moderate increase in the risk of community-acquired C diff infection.

Clostridioides difficile thrives in an environment of inflammation which found that inflammation provides nutrients for C. diff and creates an inhospitable environment for competing bacteria.

Investigators said their paper was the first systematic review and meta-analysis of C diff infection diagnostic methods in Korea.

An orally administered adsorbent to prevent antibiotic disruption of intestinal flora enters phase 3 trial against clostridium difficile (C diff) in patients with hematologic malignancies.

Contemporary care guidelines for this bacterium in geriatrics needs to be followed more closely, one study found.

Empiric broad-spectrum antimicrobial therapy, including coverage of MRSA and Pseudomonas aeruginosa, is generally recommended for healthcare-associated infections.

The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.

Therapies in the pipeline to treat C. difficile and closing thoughts on what is most exciting, in regards to better prevention and management of the condition, moving forward.

Current barriers associated with the use of fecal microbiota transplantation for C. difficile infections.

Healthcare experts comment on current data associated with emerging microbiota therapies that are currently under study for the treatment of C. difficile infections.

Panelists discuss the use of fecal microbiota transplantation as treatment for eligible patients with C. difficile.

Current gaps in the prevention/treatment of C. difficile infections, as highlighted by leading healthcare professionals.

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.

A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.

Important factors to consider when selecting an appropriate therapy to treat C. difficile.

Implications regarding how to properly treat patients with C. difficile infections based on data that has emerged since clinical practice guidelines were last updated.

Recommendations for treating C. difficile upon a first recurrence as well as following multiple recurrences based on currently available treatment options and recommendations by the IDSA/SHEA clinical practice guidelines.

A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.

Types of testing algorithms used in clinical practice to help clarify a diagnosis of C. difficile infection.

Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.

A discussion regarding the increasing frequency of C. difficile recurrence and its effects on patients and the healthcare system.

Sources of transmission and challenges that impact the management of community-onset C. difficile.

What healthcare providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.

Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.

Biologics have become a novel treatment in recurrent C. difficile.

An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.